Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Lopinavir / ritonavir · 1 trial · 2 indications
Proportion of participants with a negative high-risk human papillomavirus (hrHPV) qualitative test at 3 months post end of treatment
| Arm | Type | Description |
|---|---|---|
| DARE-HPV-LD 14 day | ACTIVE_COMPARATOR | 14 day administration of DARE-HPV low dose |
| DARE-HPV-LD 21 day | ACTIVE_COMPARATOR | 21 day administration of DARE-HPV low dose |
| DARE-HPV-HD 14 day | ACTIVE_COMPARATOR | 14 day administration of DARE-HPV high dose |
| DARE-HPV-HD 21 day | ACTIVE_COMPARATOR | 21 day administration of DARE-HPV high dose |
| Placebo 14 day | NO_INTERVENTION | 14 day administration of placebo product |
| Placebo 21 day | NO_INTERVENTION | 21 day administration of placebo product |
| Name | Type | Description |
|---|---|---|
| Lopinavir / ritonavir | DRUG | A fixed-dose ration combination (12:1) of lopinavir and ritonavir in a vaginal capsule. |
Inclusion Criteria: 1. Provision of written informed consent prior to any study-specific procedures. 2. Premenopausal women aged 22-50 years inclusive at the time of screening visit. 3. Positive result for genital hrHPV (types 16, 18, or 'other') on at least 2 tests over the span of at least 12 mon...
Lopinavir / ritonavir is being studied for the treatment of high-risk persistent Human Papillomavirus (HPV) infection. It is in Phase 2 clinical development as an investigational therapy for this indication, with a clinical trial evaluating its preliminary efficacy in women with high-risk HPV.
Lopinavir / ritonavir is a small molecule combination therapy. It is being investigated for its potential antiviral effects against high-risk Human Papillomavirus (HPV) infection, though the specific molecular target for this indication has not been disclosed.
Lopinavir / ritonavir is being developed by Dare Bioscience, Inc. (NASDAQ: DARE). The company is conducting a Phase 2 clinical trial of the drug for the treatment of high-risk persistent Human Papillomavirus (HPV) infection.
Lopinavir / ritonavir is in Phase 2 clinical development. It is an investigational drug being studied for high-risk persistent Human Papillomavirus (HPV) infection, and it has not been approved by the FDA for this use.
Lopinavir / ritonavir is being evaluated in a Phase 2 clinical trial with the identifier NCT07601074. The study, titled 'A Study of the Preliminary Efficacy of DARE-HPV to Treat High-risk Persistent Human Papillomavirus (hrHPV)', is a randomized, double-blind, active-controlled trial enrolling 118 female participants in the United States.
Yes, Lopinavir / ritonavir is being studied under the name DARE-HPV in the clinical trial NCT07601074. The trial is designed to assess the preliminary efficacy of DARE-HPV in treating high-risk persistent Human Papillomavirus (hrHPV) infection.